After 1- and 6-Month Gains, Gene Editing Companies Await Q3 Results
As developers of gene editing therapies and other genetic medicines get set to report third quarter earnings in…
Thermo Fisher-Tufts Study Links CRO-CDMO Platform to Shorter Cancer Drug Development Timeframe
Thermo Fisher Scientific says addressing the need for prefilled syringes is among potential production bottlenecks, the company is…